lazabemide has been researched along with Parkinson Disease in 12 studies
*Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Legoabe, LJ; Petzer, A; Petzer, JP; Qhobosheane, MA | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Hoon, M; Petzer, A; Petzer, JP; Viljoen, F | 1 |
| LeWitt, PA | 1 |
| Counsell, CE; Ives, N; Macleod, AD; Stowe, R | 1 |
| Alexoff, D; Fowler, JS; Logan, J; MacGregor, RR; Pappas, N; Schlyer, DJ; Shea, C; Volkow, ND; Wang, GJ; Wolf, AP | 1 |
| Ogawa, N | 1 |
| Da Prada, M | 1 |
5 review(s) available for lazabemide and Parkinson Disease
| Article | Year |
|---|---|
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
Clinical trials of neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone | 2004 |
Monoamine oxidase B inhibitors for early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Selegiline | 2005 |
[New anti-parkinsonian drugs].
Topics: Antiparkinson Agents; Bromocriptine; Humans; Lisuride; Parkinson Disease; Pergolide; Picolinic Acids; Selegiline | 1991 |
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
3 trial(s) available for lazabemide and Parkinson Disease
| Article | Year |
|---|---|
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids | 1994 |
A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
Topics: Activities of Daily Living; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Severity of Illness Index | 1993 |
Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Treatment Outcome | 1996 |
4 other study(ies) available for lazabemide and Parkinson Disease
| Article | Year |
|---|---|
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Topics: Chemistry Techniques, Synthetic; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quinazolinones; Structure-Activity Relationship | 2018 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; HeLa Cells; Humans; Levodopa; Male; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Permeability; Picolinic Acids; Prodrugs; Solubility; Structure-Activity Relationship | 2017 |
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
Topics: Aged; Antiparkinson Agents; Brain; Carbon Radioisotopes; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Picolinic Acids; Reference Values; Selegiline; Tomography, Emission-Computed | 1993 |